Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

20132,236 citationsJournal Articlebronze Open Access

Authors

John C. Byrd · The Ohio State University

Richard R. Furman · Cornell University

Steven Coutré · Stanford University

Ian W. Flinn · Sarah Cannon Research Institute

Jan A. Burger · The University of Texas MD Anderson Cancer Center

Kristie A. Blum

Barbara Grant · University of Vermont

Abstract

Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 1, pp. 32-42

DOI: 10.1056/nejmoa1215637

Field-Weighted Citation Impact: 126.62